<br/>The bioactive compound GW3965 is well known as a synthetic Liver X Receptor (LXR) agonist. <i>In vivo </i>studies have demonstrated its ability to prevent the development of atherosclerotic lesions in murine models. A major drawback of small molecule agonists like GW3965, however, is that they can activate nuclear LXR, which has been linked to the increase of fatty liver in patients with cardiovascular disease (CVD). We are exploring the use of an inorganic LXR ligand hybrid that is nucleus impermeable to take advantage of the therapeutic properties of GW3965 without its associated side effects. We will describe the gram-scale synthesis of GW3965 from commercially available starting materials in good yields. This compound will be used to form novel rhodium tetracarboxylate paddlewheel complexes.  It is expected that these new organometallic complexes can exhibit selectivity toward non-nuclear LXRs and further animal studies can determine their potential effectiveness in treating CVD.<br/>

Development of novel rhodium-based liver X receptor agonists

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.